Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Crispr Therapeutics AG (CRSP)
NASDAQ:CRSP
RESEARCH TOOLSreports
Holding CRSP?
Track your performance easily
CRSP Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$37.55 - $91.10
Previous Close$49.87
Volume622.70K
Average Volume (3M)1.23M
Market Cap
$4.20B
Enterprise Value$2.48B
Total Cash (Recent Filing)$2.00B
Total Debt (Recent Filing)$231.30M
Price to Earnings (P/E)―
Beta1.96
Next Earnings
Oct 30, 2024EPS Estimate
-$1.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.23
Shares Outstanding85,168,158
10 Day Avg. Volume1,005,772
30 Day Avg. Volume1,231,906
Standard Deviation0.20
R-Squared0.19
Alpha-0.00272
Financial Highlights & Ratios
Price to Book (P/B)2.14
Price to Sales (P/S)20.23
Price to Cash Flow (P/CF)-10.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue12.32
Enterprise Value/Gross Profit10.33
Enterprise Value/Ebitda-11.43
Forecast
1Y Price Target
$74.00Price Target Upside50.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
Crispr Therapeutics AG News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceStrong balance sheet with approximately $2 billion in cash and equivalents coupled with near-term Casgevy revenues offers robust support in navigating macroeconomic challenges.
Pipeline ProgressCRISPR's diversified pipeline includes second-generation allogeneic products like CTX112 and CTX131, with ongoing studies and potential data readouts providing significant upside potential.
Regulatory ApprovalsCasgevy is currently approved in the U.S., Great Britain, the EU, the Kingdom of Saudi Arabia, and the Kingdom of Bahrain for the treatment of both sickle cell disease and transfusion-dependent β-thalassemia, with ongoing launches.
Bears Say
Product LaunchExpectations remain cautious on the Casgevy launch as the patient numbers need to increase dramatically, and they need to translate to sales.
Revenue ExpectationsRevenue expectations for Casgevy may fall short due to lagged revenue recognition dynamics.
Sales PerformanceNo Casgevy sales were reported in 2Q:24.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CRSP FAQ
What was Crispr Therapeutics AG’s price range in the past 12 months?
Crispr Therapeutics AG lowest stock price was $37.55 and its highest was $91.10 in the past 12 months.
What is Crispr Therapeutics AG’s market cap?
Currently, no data Available
When is Crispr Therapeutics AG’s upcoming earnings report date?
Crispr Therapeutics AG’s upcoming earnings report date is Oct 30, 2024 which is in 42 days.
How were Crispr Therapeutics AG’s earnings last quarter?
Crispr Therapeutics AG released its earnings results on Aug 05, 2024. The company reported -$1.49 earnings per share for the quarter, missing the consensus estimate of -$1.427 by -$0.063.
Is Crispr Therapeutics AG overvalued?
According to Wall Street analysts Crispr Therapeutics AG’s price is currently Undervalued.
Does Crispr Therapeutics AG pay dividends?
Crispr Therapeutics AG does not currently pay dividends.
What is Crispr Therapeutics AG’s EPS estimate?
Crispr Therapeutics AG’s EPS estimate is -$1.42.
How many shares outstanding does Crispr Therapeutics AG have?
Crispr Therapeutics AG has 85,168,160 shares outstanding.
What happened to Crispr Therapeutics AG’s price movement after its last earnings report?
Crispr Therapeutics AG reported an EPS of -$1.49 in its last earnings report, missing expectations of -$1.427. Following the earnings report the stock price went down -0.665%.
Which hedge fund is a major shareholder of Crispr Therapeutics AG?
Among the largest hedge funds holding Crispr Therapeutics AG’s share is ARK Investment Management LLC. It holds Crispr Therapeutics AG’s shares valued at 420M.
---
Crispr Therapeutics AG Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$74.00 (50.10% Upside)
$74.00 (50.10% Upside)
Blogger Sentiment
Bullish
CRSP Sentiment 98%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 226.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-1.40%
12-Months-Change
Fundamentals
Return on Equity
-14.00%
Trailing 12-Months
Asset Growth
6.50%
Trailing 12-Months
Company Description
Crispr Therapeutics AG
CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.
---
CRSP Stock 12 Month Forecast
Average Price Target
$74.00
▲(50.10% Upside)
Technical Analysis
Beam Therapeutics
―
Arrowhead Pharmaceuticals
―
Editas Medicine
―
Sangamo Biosciences
―
Best Analysts Covering CRSP
1 Year
1 Year Success Rate
9/15 ratings generated profit
1 Year Average Return
+21.52%
initiated a buy rating 2 months ago
Copying Anthony Butler's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +21.52% per trade.
---